Toxoplasma gondii Serology and Outcomes After Heart Transplantation: Contention in the Literature

Chehrazi‐Raffle, Alex; Luu, Minh B.; Yu, Zhenhua; Liou, Frank W.; Kittleson, M.; Hamilton, M.; Kobashigawa, Jon A.

doi:10.1016/j.transproceed.2015.06.022

Cited by 23 publications

(20 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, our study did not address long-term survival, which at 5 years after transplantation was reportedly poorer for D+/R– than for D–/R– heart transplant recipients ( 17 ). In that study, Chehrazi-Raffle et al ( 17 ) did not record the duration of chemoprophylaxis, a parameter that could be of greater interest. Similarly, only 18 HSCT patients received chemoprophylaxis, although 45 were known to be seropositive ( Table 3 ).…”

Section: Discussionmentioning

confidence: 95%

Toxoplasmosis in Transplant Recipients, Europe, 2010–2014

Robert‐Gangneux¹,

Meroni²,

Dupont³

et al. 2018

Emerg. Infect. Dis.

104

100

View full text Add to dashboard Cite

Transplantation activity is increasing, leading to a growing number of patients at risk for toxoplasmosis. We reviewed toxoplasmosis prevention practices, prevalence, and outcomes for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT; heart, kidney, or liver) patients in Europe. We collected electronic data on the transplant population and prevention guidelines/regulations and clinical data on toxoplasmosis cases diagnosed during 2010–2014. Serologic pretransplant screening of allo-hematopoietic stem cell donors was performed in 80% of countries, screening of organ donors in 100%. SOT recipients were systematically screened in 6 countries. Targeted anti-Toxoplasma chemoprophylaxis was heterogeneous. A total of 87 toxoplasmosis cases were recorded (58 allo-HSCTs, 29 SOTs). The 6-month survival rate was lower among Toxoplasma-seropositive recipients and among allo-hematopoietic stem cell and liver recipients. Chemoprophylaxis improved outcomes for SOT recipients. Toxoplasmosis remains associated with high mortality rates among transplant recipients. Guidelines are urgently needed to standardize prophylactic regimens and optimize patient management.

show abstract

Section: Discussionmentioning

confidence: 95%

Toxoplasmosis in Transplant Recipients, Europe, 2010–2014

Robert‐Gangneux¹,

Meroni²,

Dupont³

et al. 2018

Emerg. Infect. Dis.

104

100

View full text Add to dashboard Cite

show abstract

“…The literature regarding parasitic infections with toxoplasmosis is controversial. 43 Strongyloides can be managed with recipient prophylaxis or preemptive treatment for donor-positive serology. 44,45 In contrast, Trypanosoma cruzi donors (Chagas disease) should not be used.…”

Section: Parasitesmentioning

confidence: 99%

ISHLT consensus statement on donor organ acceptability and management in pediatric heart transplantation

Kirk

Dipchand

Davies

et al. 2020

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…A variety of malignancies, including lymphoma, leukemia, and myeloma, can reactivate toxoplasmosis (Maciel et al, 2000; Kojima et al, 2010). Transplantation of an organ from seropositive donor can activate latent infection in a seronegative recipient receiving immunotherapy (Chehrazi-Raffle et al, 2015). Transplantation of an organ from seronegative donor can also initiate fatal infection by activation of the latent infection in a seropositive recipient receiving immunosuppressive therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Transplantation of an organ from seronegative donor can also initiate fatal infection by activation of the latent infection in a seropositive recipient receiving immunosuppressive therapy. It seems that danger of transplanting an infected organ into a seronegative recipient is greater than that of transplanting a non-infected organ into a seropositive recipient (Chehrazi-Raffle et al, 2015). Fatal toxoplasmosis has been reported in heart, liver and bone marrow, haematopoietic stem cell transplant recipients (Castagnini et al, 2007; Caner et al, 2008; Stajner et al, 2013; Gajurel et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis

Wang¹,

Liu

Ma³

et al. 2017

Front. Microbiol.

184

190

View full text Add to dashboard Cite

Toxoplasma gondii has been suggested as an important opportunistic pathogen in immunocompromised patients. We conducted a global meta-analysis to assess the prevalence and odds ratios (ORs) of T. gondii infection in immunocompromised individuals. Electronic databases were reviewed for T. gondii infection in HIV/AIDS patients, cancer patients, and transplant recipients, and meta-analyses were conducted to calculate overall estimated prevalence and ORs using random or fixed-effects models. Totally, 72 eligible studies were included. The estimated pooled prevalence of T. gondii infection in immunocompromised patients and the control was 35.9 and 24.7% (p < 0.001), with an OR of 2.24, i.e., 42.1 and 32.0% for HIV/AIDS patients and the control (p < 0.05), 26.0 and 12.1% for cancer patients and the control (p < 0.001), and 42.1 and 34.5% for transplant recipients and the control (p > 0.05), whose estimated pooled ORs were 1.92 (95% CI, 1.44–2.55), 2.89 (95% CI, 2.36–3.55), and 1.51 (95% CI, 1.16–1.95), respectively. This study is the first to demonstrate that the immunocompromised patients are associated with higher odds of T. gondii infection, and appropriate prevention and control measures are highly recommended for these susceptible populations.

show abstract

Toxoplasma gondii Serology and Outcomes After Heart Transplantation: Contention in the Literature

Cited by 23 publications

References 13 publications

Toxoplasmosis in Transplant Recipients, Europe, 2010–2014

Toxoplasmosis in Transplant Recipients, Europe, 2010–2014

ISHLT consensus statement on donor organ acceptability and management in pediatric heart transplantation

Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About